 "Tata Medical in talks to launch Moderna Covid-19 vaccine in India: Report")
(Reuters) - Tata Medical & Diagnostics is said to have started initial discussions with Moderna Inc for a partnership to launch its COVID-19 vaccine in India, the Economic Times reported on Monday.
Tata could team up with the India's Council of Scientific & Industrial Research (CSIR) to carry out clinical trials of Moderna's vaccine candidate in India, the report https://bit.ly/2Yd8E2B added, citing officials familiar with the matter.
The Indian government this month gave emergency-use approval to a COVID-19 vaccine developed by Bharat Biotech International Ltd and state-run Indian Council of Medical Research, and another licensed from Oxford University and AstraZeneca PLC that is being manufactured by the Serum Institute of India.
Moderna did not respond to Reuters' request for a comment outside business hours, while Tata Medical & Diagnostics did not immediately respond.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app